In addition, a recent meta-analysis showed that a higher level of sPD-L1 is associated with worse overall survival of cancer patients (11), indicating that sPD-L1 may work as a systemic suppressor of anti-tumor immunity, in addition to local suppression of anti-tumor immunity by membrane-bound PD-L1 on cancer cells. This evidence concerns the gene CD274 and cancer.